Well done, Jake, thanks for posting. Question: Besides Merck, do you have any other top big pharma picks that would be good partners for us on a particular indication?

If so - who among them might be the most motivated to want to team up?

With Leronlimab's potential as a platform drug, I'd be surprised if there wasn't a lot of jockeying for position among the BP's while we're so cheap.